Swiss pharmaceutical company, Idorsia, has enrolled its first patient into a multiple-dose study to evaluate the efficacy and safety of cenerimod for the treatment of adults with systemic lupus erythematosus (SLE). An oral once-daily tablet, cenerimod has shown to reduce key immune system cells that contribute to inflammation of organs and tissues. The study aims to enroll 500 patients who will be treated for up to 12 months and to validate the appropriate dose, patient population and endpoints for further development in SLE. Continue to follow the Lupus Foundation of America for updates on cenerimod.

Read the news